Does Dr. Giangiulio study HIV treatment and its effects?

Yes, he focuses on how different HIV medications impact weight and overall health.

What are INSTIs and how are they related to his research?

INSTIs are a newer class of HIV medications. Dr. Giangiulio studies their long-term effects on weight in patients.

Is Dr. Giangiulio's work relevant for HIV patients concerned about weight?

Absolutely, his research provides valuable insights into how HIV treatments can affect body weight over time.

DR. DENNIS JOSEPH GIANGIULIO, M.D.

EASTON, PA

Research Active

Internal Medicine - Hematology & Oncology NPI registered 21+ years 1 publication 2025 – 2025 NPI: 1326041153

Internal Medicine - Hematology & Oncology

Body Mass Index Longitudinal Studies Body Weight HIV Infections Piperazines Pyridones HIV Integrase Inhibitors Weight Gain Raltegravir Potassium Heterocyclic Compounds, 3-Ring Oxazines Dolutegravir

Practice Location

1600 RIVERSIDE CIR
EASTON, PA 18045-5671

Phone: (484) 503-4500

What does DENNIS GIANGIULIO research?

Dr. Giangiulio studies the effects of HIV medications, particularly the difference between older treatments and newer ones. In his research, he investigates how switching to integrase strand transfer inhibitors (INSTIs), a newer class of HIV medications, affects weight in individuals living with HIV. By analyzing long-term data, he aims to understand the implications of these treatments on the health and well-being of patients who are managing HIV.

Key findings

Patients who switched to INSTIs gained an average of 6.9 kg (15.2 lbs) over 12 years compared to those who remained on older medications.
The study involved a retrospective cohort of 89 individuals, highlighting real-life weight trends in people with HIV.
Weight changes in patients taking INSTIs may require monitoring to manage potential health risks associated with weight gain.

Frequently asked questions

Does Dr. Giangiulio study HIV treatment and its effects?: Yes, he focuses on how different HIV medications impact weight and overall health.
What are INSTIs and how are they related to his research?: INSTIs are a newer class of HIV medications. Dr. Giangiulio studies their long-term effects on weight in patients.
Is Dr. Giangiulio's work relevant for HIV patients concerned about weight?: Absolutely, his research provides valuable insights into how HIV treatments can affect body weight over time.

Publications in plain English

Real-Life Long-Term Weight Trends After Switching to INSTI-Based Therapy in People Living with HIV: A 12-Year Retrospective Cohort Study.

2025

The new microbiologica

Ceccarelli G, Branda F, Bortolani L, Albanese M, De Angelis I +12 more

Plain English
This study looked at how switching from older HIV medications (protease inhibitors) to newer ones (integrase strand transfer inhibitors, or INSTIs) affected weight in people living with HIV over 12 years. Researchers followed 89 individuals and found that those who switched to INSTIs gained more weight, with an average body weight increase of about 6.9 kg (15.2 lbs) compared to those who stayed on the older medications. These findings are important because they demonstrate that while INSTIs are generally safe and effective, there is a need to monitor weight changes in patients taking these treatments. Who this helps: This helps patients living with HIV by providing insights into the effects of their medication on weight.

PubMed

Frequent Co-Authors

Giancarlo Ceccarelli Francesco Branda Luca Bortolani Mattia Albanese Irene De Angelis Myriam Maiorano Riccardo Donà Edoardo Bogliolo Francesco Romano Paolo Vassalini

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.